Company and Stock Identity

How Boehringer Ingelheim Connects to the Public Market

Company structure
Private company, not independently verified
Market access
No current public listing was verified.
Research focus
Read this one against the group test: how far did the work actually go. Boehringer Ingelheim is past the pilot stage with both of its named AI partners. The Owkin deal is a signed licence covering oncology and immunology data. The Brainomix work goes further than most, because e-Lung was picked to measure a co-primary endpoint in a Phase 3 trial, which means a regulator will eventually look at numbers the software produced. That is a much heavier use of AI than a research assistant, and it is the one worth following. Because the company publishes nothing this desk can read, every claim here has to be checked against the partner announcement it came from.

This is an honest gap, not a finding. Every Boehringer Ingelheim corporate page tried on 2026-10-31 returned a bot block: the group site, the United States, Canadian and United Kingdom sites, the animal health site and even the robots file all answered 403 Forbidden to three separate runs of this desk. The only company page that would open is its jobs site, whose footer gives the legal entity as Boehringer Ingelheim GmbH, a German private limited company, and which showed 683 open roles. A GmbH is not a listed company, and no listing was found, so this record says a listing was not verified rather than guessing at the ownership. Every other fact in this profile comes from announcements by Owkin and Brainomix, named below. Checked on 2026-10-31.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Brainomix ... Company source

Brainomix says Phase III lung trial data shows CT measurement can track fibrosis

Brainomix said on 1 October 2026 that new data from the Phase III INBUILD trial highlights the potential of quantitative CT to predict disease progression and assess treatment response in progressive pulmonary fibrosis. The trial is a Boehringer Ingelheim study, and Brainomix has described an ongoing partnership with that company in pulmonary fibrosis since May 2026. The announcement states the potential and the two intended uses but does not publish any effect sizes, accuracy figures or outcome numbers, and makes no regulatory claim for the use it describes.

Why it matters: A drug trial using an imaging measurement as a way to judge whether treatment is working is a different and more valuable business than selling software to a hospital, because a sponsor will pay for a measurement it can defend to a regulator. That is why this is worth watching even without figures. The absence of figures is also the point: predicting progression from a CT scan is a research finding here, not a cleared use, and the company's FDA-cleared e-Lung product measures features on a scan rather than forecasting a disease course. Wait for the published analysis before treating this as established.

... Owkin ... Company source

Owkin licenses K Pro plus oncology and immunology data to Boehringer Ingelheim

Owkin said on 2 September 2026 that it will license K Pro, which it calls its AI Scientist, to Boehringer Ingelheim together with multimodal patient data. Owkin says the agreement covers licensing its existing multimodal cancer data, generating new multimodal immunology data, and giving Boehringer Ingelheim access to K Pro for analysis and repeatable research across several cancer and immunology conditions. It says the agreement follows a 2025 pilot in which Owkin supplied spatial tumour microenvironment findings from its MOSAIC dataset. Thomas Clozel, the Owkin co-founder and chief executive, is quoted saying the agreement shows how advanced AI has the potential to enable research driven by data. No deal value, term length or figures are disclosed.

Why it matters: The part that is different here is the new data. Licensing a dataset that already exists is a purchase. Paying somebody to generate immunology data that does not exist yet is a research programme with a schedule and a risk, and it means Boehringer Ingelheim wanted something it could not buy off a shelf. That is a stronger signal of intent than a software licence. What is missing is everything a reader would use to judge it: no term, no money, no named condition, and no measure of what the 2025 pilot actually produced beyond the word findings. Repeatable research is also a claim worth holding the companies to, because the usual complaint about this kind of analysis is that nobody can run it again and get the same answer.

... Brainomix ... Company source

Brainomix widens its lung fibrosis partnership with Boehringer Ingelheim into a multi site study

Brainomix said on 12 May 2026 that it and Boehringer Ingelheim are broadening their partnership in pulmonary fibrosis. The company says the wider agreement builds on early results it describes as showing the potential of its e-Lung software to allow earlier diagnosis of progressive pulmonary fibrosis. It says the next stage, called PROGRESS-PPF, is a forward looking study across several centres designed to produce evidence of the clinical impact of e-Lung at scale, with deployments planned across numerous sites in the United States. The page is a short summary. It names no participating sites, no patient numbers, no timetable and no results.

Why it matters: A study that sets out to measure clinical impact is a harder test than the one that came before it, and the company chose to take it. Earlier diagnosis only matters if something changes for the patient, and that is what a prospective multi centre study can show and an early result cannot. Read the wording carefully though. Potential to allow earlier diagnosis is the company describing its own early findings, not a proven result, and this desk has seen no data behind it. There is also a plain commercial reading: the drug company that sells treatment for this condition benefits when more people are found earlier, so the partner funding the evidence has a stake in the answer. That does not make the study wrong. It makes independent sites and published numbers the things to wait for.

... Brainomix ... Company source

Brainomix e-Lung is chosen as a co-primary endpoint in a Boehringer Ingelheim Phase 3 lung trial

Brainomix said on 20 January 2026 that its e-Lung software had been selected by Boehringer Ingelheim to provide AI derived imaging measures as a co-primary endpoint in the DROP-FPF Phase 3 trial in pulmonary fibrosis. The company says DROP-FPF is the first Phase 3 trial in interstitial lung disease to use automated, quantitative high resolution CT imaging measures as a co-primary endpoint, and calls the selection a milestone in how these trials are designed. The announcement names no patient numbers, no sites, no timetable and no results, and does not state any regulatory status for the software.

Why it matters: A co-primary endpoint is one of the two measures a trial succeeds or fails on, so this puts software where a regulator will eventually have to look at it. That is a much bigger commitment than using AI to triage scans or draft a report, and it is rare. The reason it matters beyond this one trial is precedent: if an automated CT measure can carry an endpoint in lung disease, the same argument gets made in every other field with a scan and a slow disease. Two cautions. Being chosen is not being validated, and the announcement offers no data on how the measure performs or how it compares with the human reading it replaces. And a single trial sponsor picking a tool is a commercial decision, not an independent assessment. The result that matters is whether the trial reads out and whether regulators accept the measure.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The jobs site was the only Boehringer Ingelheim page that would open. It showed 683 open roles across quality assurance, information technology, clinical science, project management and engineering, sales and medical representation, human resources, compliance and manufacturing, in the United States, Canada, Germany, the United Kingdom, Poland, the Philippines, Taiwan, Japan, China, Malaysia and Australia, with listings in Ingelheim, Ridgefield in Connecticut, Gainesville and Athens in Georgia, Columbus in Ohio, Saint Joseph in Missouri, Burlington, Wroclaw, Taipei, Taichung, Shanghai, Shinagawa, Muntinlupa, Kota Kinabalu, Brisbane and Pirbright.

Qualification signal: The AI work here sits inside clinical trials, not inside a software team, so the useful experience is imaging biomarkers and trial endpoints rather than model building. Anyone who has helped get a measurement accepted by a regulator is worth more to this company than someone who has shipped a consumer feature. A role title alone will not tell you which side you are on, so ask which trial or product the job supports.

Check current roles at Boehringer Ingelheim. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources